WASHINGTON — The Trump administration permanently filled four key leadership roles at the Food and Drug Administration on Tuesday, after it nominated Heidi Overton to lead the agency late last month.
Three of the officials are serving in an acting capacity, and will take the same roles permanently, the administration said. They are Michael Davis, a psychiatrist who will be director of the Center for Drug Evaluation and Research; former Merck official Karim Mikhail, who will be director of the Center for Biologics Evaluation and Research; and Bret Koplow, an attorney who has been at the FDA since 2011, and will serve as director of the Center for Tobacco products.
The fourth appointee, Jared Seehafer, will serve as the FDA’s first Deputy Commissioner for Technology and Artificial Intelligence. He joined the FDA as an advisor in 2025 after founding a life science software company and working in investment advising in biotech, according to his Linkedin. Under the Trump administration, the agency has pushed for its staff to use AI to speed up its review processes.
